Show simple item record

dc.contributor.authorJoshi, PM
dc.contributor.authorDesai, D
dc.contributor.authorFuziwara, S
dc.contributor.authorRaveenthiran, S
dc.contributor.authorNafea, M
dc.contributor.authorKulkarni, SB
dc.date.accessioned2022-03-16T00:38:53Z
dc.date.available2022-03-16T00:38:53Z
dc.date.issued2021
dc.identifier.issn2149-3235
dc.identifier.doi10.5152/tud.2021.21065
dc.identifier.urihttp://hdl.handle.net/10072/413267
dc.description.abstractObjective: To define the role of tadalafil in improving outcomes of redo urethroplasty for pelvic fracture urethral injury (PFUI). PFUI is common in developing countries, invariably as a result of road traffic trauma. Repair is complex, and redo cases are even more challenging. Material and methods: This was a longitudinal prospective nonrandomized study between 2017 and 2019. Men undergoing redo-urethroplasty were nonrandomized into two groups. Group 1 received tadalafil 5 mg the next day after surgery and continued for 3 months, and group 2 did not receive tadalafil. Inclusion criteria were patients undergoing redo-urethroplasty willing to trial low-dose tadalafil post-operatively. Exclusion criteria were <18 years, females, primary cases, and complex cases such as recto-urethral fistula. Average follow-up was 19.5 months. Results: Sixty patients were enrolled (29 in group 1 and 31 in group 2). Mean age was 31 years. These patients had 1-3 prior failed urethroplasties. Most required step 3 anastomotic urethroplasty (68.3%). Success was defined as absence of symptoms and no need for surgical intervention. Failure was defined as redo ure-throplasty or >1 endoscopic intervention. Primary success was 83.3%. Success with tadalafil was 96.6%, compared to 71.0% in the non-Tadalafil group (P = .0008). Only one patient on tadalafil failed, compared with nine in the non-tadalafil group. Secondary success rate was defined as the need for a single subsequent endoscopic intervention and was 93.3%. Conclusion: In our series, there was improved outcome with using tadalafil in patients having redo urethro-plasty for PFUI. Further trials should be done to evaluate the use in all PFUI cases.
dc.description.peerreviewedYes
dc.publisherTurkish Association of Urology
dc.relation.ispartofpagefrom319
dc.relation.ispartofpageto324
dc.relation.ispartofissue4
dc.relation.ispartofjournalTurkish Journal of Urology
dc.relation.ispartofvolume47
dc.subject.fieldofresearchSurgery
dc.subject.fieldofresearchNephrology and urology
dc.subject.fieldofresearchcode320226
dc.subject.fieldofresearchcode320214
dc.titleRedo pelvic fracture urethral injury repair: The case for tadalafil
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationJoshi, PM; Desai, D; Fuziwara, S; Raveenthiran, S; Nafea, M; Kulkarni, SB, Redo pelvic fracture urethral injury repair: The case for tadalafil, Turkish Journal of Urology, 2021, 47 (4), pp. 319-324
dcterms.licensehttps://creativecommons.org/licenses/by/4.0/
dc.date.updated2022-03-15T23:39:59Z
dc.description.versionVersion of Record (VoR)
gro.rights.copyright© The Author(s) 2021. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
gro.hasfulltextFull Text
gro.griffith.authorDesai, Devang


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record